TriVerity

The TriVerity test is an automated in vitro diagnostic system designed to measure host response gene expression via RT-LAMP technology. It aims to differentiate bacterial, viral, and non-infectious illness, and to predict severe outcomes in patients with suspected acute infection or sepsis.

The TriVerity test, developed by Inflammatix, Inc., is an automated, semi-quantitative in vitro diagnostic system designed to measure the relative expression levels of host response genes in RNA isolated from whole blood. Utilizing reverse transcription loop-mediated isothermal amplification (RT-LAMP) on the Myrna instrument, it generates three distinct scores, each falling into one of five interpretation bands. These scores aid in differentiating bacterial infections, viral infections, and non-infectious illness, and in determining the likelihood of 7-day need for mechanical ventilation, vasopressors, and/or renal replacement therapy in adult patients presenting with suspected acute infection or sepsis. This system has been determined to be substantially equivalent to legally marketed predicate devices, allowing its marketing. Extensive analytical and clinical studies were conducted to evaluate the TriVerity test's performance. Analytical validation demonstrated robust reproducibility, specimen and reagent stability, linearity across its dynamic range, and high analytical sensitivity, with no significant interference or cross-reactivity observed. A prospective, multi-center clinical study involving over a thousand participants showed high accuracy for diagnosing bacterial and viral infections (AUROCs of 0.83 and 0.91, respectively, with consensus adjudication) and for predicting severe illness (AUROC 0.78). The test demonstrated superior accuracy compared to common biomarkers like Procalcitonin (PCT), C-Reactive Protein (CRP), and White Blood Cells (WBC), and its performance remained consistent across diverse racial and immune status groups, enhancing risk stratification for severe outcomes.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. What specific host response genes are measured by the TriVerity test, and what is the biological rationale for their selection in differentiating infection types and predicting severity?; How do the "three distinct scores" translate into the "five interpretation bands," and what specific clinical actions or decisions are recommended for each band?; What was the consensus adjudication process for confirming bacterial and viral infections in the clinical study, and how might different adjudication methods impact the reported AUROCs?; Beyond AUROCs, what are the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of the TriVerity test for both diagnostic and prognostic indications, especially in low and high prevalence settings?; Are there specific patient cohorts (e.g., immunocompromised, pediatric, specific pathogen types) where the TriVerity test's performance might differ, and what further studies are planned or needed to assess this?